Page last updated: 2024-11-04

sumatriptan and Arterial Occlusive Diseases

sumatriptan has been researched along with Arterial Occlusive Diseases in 1 studies

Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.

Arterial Occlusive Diseases: Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.

Research Excerpts

ExcerptRelevanceReference
"We report a case of ischemia limited to the upper limb caused by chronic use of ergotamine."7.71Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature. ( Alanezi, KH; Cinà, CS; Safar, HA, 2002)
"We report a case of ischemia limited to the upper limb caused by chronic use of ergotamine."3.71Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature. ( Alanezi, KH; Cinà, CS; Safar, HA, 2002)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Safar, HA1
Alanezi, KH1
Cinà, CS1

Other Studies

1 other study available for sumatriptan and Arterial Occlusive Diseases

ArticleYear
Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature.
    The Journal of cardiovascular surgery, 2002, Volume: 43, Issue:2

    Topics: Administration, Oral; Adrenergic alpha-Antagonists; Angiography; Arm; Arterial Occlusive Diseases; E

2002